WALD

ROSEN, LEADING INVESTOR COUNSEL, Encourages Waldencast plc Investors to Inquire About Securities Class Action Investigation – WALD, WALDW

Retrieved on: 
Friday, March 8, 2024

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=18362 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).
  • The investigation concerns whether Waldencast and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On January 31, 2024, Waldencast announced the departure of its Chief Financial Officer and Chief Operating Officer, Philippe Gautier, effective immediately.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Obagi Cosmeceuticals Announces the Launch of Daily Hydro-Drops® Rejuvenating Eye Gel Cream

Retrieved on: 
Thursday, March 7, 2024

LONG BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Obagi Cosmeceuticals LLC (“Obagi”), a leader in skincare innovation and the originator of medical-grade skincare and a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), today announced the launch of Daily Hydro-Drops® Rejuvenating Eye Gel Cream.

Key Points: 
  • LONG BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Obagi Cosmeceuticals LLC (“Obagi”), a leader in skincare innovation and the originator of medical-grade skincare and a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), today announced the launch of Daily Hydro-Drops® Rejuvenating Eye Gel Cream.
  • Daily Hydro-Drops® Rejuvenating Eye Gel Cream offers a transformative solution to the eye area, bringing an immediate boost in radiance, while simultaneously rejuvenating the eye area with 24-hour lasting hydration for a more awakened appearance.
  • With just one swipe, Rejuvenating Eye Gel Cream delivers brighter, smoother, and more hydrated skin around the eyes.
  • Multimodal efficacy testing was completed to demonstrate the efficacy of Daily Hydro-Drops® Rejuvenating Eye Gel Cream, revealing the below findings after various time increments:
    Daily Hydro-Drops® Rejuvenating Eye Gel Cream is now available for $75 through partnering physician channels, and will be available for customers to purchase on Obagi.com on March 21st.

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Chemours, Trupanion, and Renovaro and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 5, 2024

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Specifically, the Company is conducting an analysis regarding certain accounting issues in connection with the sale of certain Obagi products for the Vietnam market.
  • For more information on the Renovaro investigation go to: https://bespc.com/cases/RENB

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Waldencast plc Investors to Inquire About Securities Class Action Investigation – WALD, WALDW

Retrieved on: 
Friday, March 1, 2024

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=18362 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).
  • The investigation concerns whether Waldencast and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On January 31, 2024, Waldencast announced the departure of its Chief Financial Officer and Chief Operating Officer, Philippe Gautier, effective immediately.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Waldencast Receives Positive Nasdaq Listing Determination

Retrieved on: 
Monday, February 26, 2024

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that by decision dated February 22, 2024, a Nasdaq Hearings Panel (the “Panel”) granted Waldencast’s request for continued listing on The Nasdaq Stock Market LLC (“Nasdaq”), subject to Waldencast filing the interim financial statements for the six-month period ended June 30, 2023 with the Securities and Exchange Commission by April 1, 2024, and Waldencast’s continued compliance with all other applicable criteria for continued listing on Nasdaq.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that by decision dated February 22, 2024, a Nasdaq Hearings Panel (the “Panel”) granted Waldencast’s request for continued listing on The Nasdaq Stock Market LLC (“Nasdaq”), subject to Waldencast filing the interim financial statements for the six-month period ended June 30, 2023 with the Securities and Exchange Commission by April 1, 2024, and Waldencast’s continued compliance with all other applicable criteria for continued listing on Nasdaq.
  • Waldencast is diligently working to evidence compliance with the terms of the Panel’s decision as soon as practicable and in any event by no later than April 1, 2024.

Waldencast’s (WALD) CFO/COO Gautier Abruptly Exits Amid SEC’s Investigation into Company’s Improper Accounting - Hagens Berman

Retrieved on: 
Thursday, February 22, 2024

SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .
  • On Jan. 31, 2024, Waldencast announced that Philippe Gautier, its current chief financial officer and chief operating officer, was leaving the company, effective immediately.
  • The company explained that the misreporting stemmed from improper revenue recognition involving sales of its Obagi skincare products to its Southeast Asia distributor.
  • “We are investigating whether Waldencast may have intentionally overstated revenues to appear more profitable,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Waldencast Announces New “Creative Council” of Industry Pioneers and Disruptors

Retrieved on: 
Thursday, February 22, 2024

NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or “the Company”), a global multi-brand beauty and wellness platform, today announced the formation of a new Creative Council.

Key Points: 
  • NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or “the Company”), a global multi-brand beauty and wellness platform, today announced the formation of a new Creative Council.
  • The interdisciplinary team of industry disruptors will come together to help Waldencast stay ahead of the curve by ideating on long-term macro and micro-trends in the beauty and wellness industry, and to ensure the Company evolves to meet customer needs now and in the future.
  • The Creative Council will focus on what is next in beauty, wellness, and culture.
  • To learn more about the Waldencast Creative Council, please visit this page .

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, and Chemours and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, February 21, 2024

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), and The Chemours Company (NYSE: CC).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), and The Chemours Company (NYSE: CC).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Specifically, the Company is conducting an analysis regarding certain accounting issues in connection with the sale of certain Obagi products for the Vietnam market.